If investing in big pharma were like shopping at a clearance sale, Merck & Co. would be that high-end brand with the 50% off tag no one can believe is real. Despite being a $200 billion juggernaut with a portfolio that could rival an entire hospital, the market has been treating Merck like it’s yesterday’s news. Why? That’s what we’re here to unpack. Buckle up—because Merck might just be the biggest value play on the shelf. Chapter 1: The Colossus With a Lab Coat Merck & Co. is no rookie. Founded in 1891, it’s been battling disease before your great-grandparents had electricity. This isn’t just another pharmaceutical company; it’s one of the architects of modern medicine. From vaccines to antivirals to groundbreaking cancer treatments, Merck has done it all. Its contributions to global health read like a Nobel Prize resume. Keytruda? That’s theirs. Gardasil? Also theirs. Januvia? Yup. Merck’s pipeline isn’t just full; it’s overflowing with life-saving molecules, treatments, and...